Agilent Technologies, Inc. Shareholders: Ownership Structure, Brands, and Acquisition History
Last updated: August-2026Ownership Structure
Stakes approximate based on latest filings.
Ownership Analysis
Agilent Technologies is a straightforward widely held public company. No family or founder controls it, and voting power follows economic ownership on a one-share one-vote basis. The largest holders are the major index managers, Vanguard, BlackRock and State Street, whose positions reflect Agilent membership in the leading benchmarks.The company traces its structure to a corporate separation rather than a founding. Hewlett-Packard spun off its test and measurement, chemical analysis and related businesses as Agilent in 1999, and the two were fully separated by 2000. Leadership rests with a professional management team under chief executive Padraig McDonnell, who took the role in 2024, with an independent board chaired by Koh Boon Hwee.For investors the ownership structure means strategy is judged by the market. Agilent has repeatedly reshaped itself to satisfy shareholders, most notably by spinning off its electronic measurement arm in 2014, and its current focus on higher-growth life sciences and diagnostics reflects that market accountability. The Ignite operating transformation is aimed at lifting margins and returns for a dispersed base.
Direct Owners
Institutional Shareholders
Shareholder Analysis
Agilent shareholder base is anchored by passive institutional capital. Vanguard, BlackRock, State Street and Geode hold the largest positions, driven by the company weight in the major indices, and together the big index families own a meaningful minority. These holders provide a stable foundation.Active investors own Agilent as a quality compounder in life sciences tools, drawn to its recurring revenue from services and consumables. In fiscal 2025 the company grew revenue nearly 7 percent to 6.95 billion dollars and posted GAAP net income of 1.30 billion dollars, with the CrossLab services and consumables business providing a durable, high-margin base that active holders prize for its stability.Governance follows conventional norms with an independent board. Because no controlling owner exists, capital return through dividends and buybacks is a primary lever management uses to reward shareholders. The debate among owners has centered on the pace of recovery in instrument demand and on execution of the Ignite transformation, which targets structurally higher margins.
Brands, Subsidiaries & Companies Owned
| Name | Type | Description |
|---|
Portfolio Analysis
Agilent competes through three market-facing groups rather than consumer brands. Following a fiscal 2025 reorganization, the business is arranged into the Life Sciences and Diagnostics Markets Group, the Agilent CrossLab Group and the Applied Markets Group, aligning the company to end markets rather than product lines.The Agilent CrossLab Group is the strategic anchor, providing services, software and consumables across the large installed base of laboratory instruments. This recurring franchise, which generates the single largest slice of revenue, gives Agilent earnings stability that pure instrument sales cannot, and it is the fastest-compounding part of the portfolio.The instrument and diagnostics franchises supply the differentiated technology. Agilent holds strong positions in chromatography, mass spectrometry and cancer diagnostics through the Dako pathology business, and it has extended into cell analysis with BioTek and biologics manufacturing with BIOVECTRA. The portfolio strategy leans on recurring services and consumables while using instrument and diagnostics innovation to expand the installed base.
Market Share & Competitors
Bubble size reflects relative market share.
| Company | Market Share | Revenue | Key Strength |
|---|
Competitive Analysis
Agilent competes among the leading life sciences tools companies, positioned behind the larger Thermo Fisher Scientific and Danaher but with deep strength in analytical instrumentation. With fiscal 2025 revenue of 6.95 billion dollars, it holds top positions in chromatography and mass spectrometry and competes with specialists such as Waters and Bruker.Its competitive edge is the combination of leading instrument technology with a large recurring services and consumables base through CrossLab, which locks in customers and smooths revenue across instrument cycles. That razor-and-blade dynamic is central to its investment case and differentiates it from competitors more reliant on capital equipment sales.The risks are cyclical and macro-driven. Instrument demand swings with pharmaceutical and academic budgets, and Agilent has navigated soft capital spending, tariffs and research-funding uncertainty. Its competitive answer is the Ignite transformation to lift margins, continued investment in recurring franchises, and a disciplined acquisition program, positioning it to gain share as instrument demand normalizes.
Acquisitions
Bubble size reflects relative deal value.
| Company Acquired | Deal Value | Year | Description |
|---|
Acquisitions Analysis
Agilent has used acquisitions to build out its life sciences and diagnostics portfolio while exiting legacy markets. The 2012 purchase of Dako for roughly 2.2 billion dollars established a cancer-diagnostics and tissue-staining business that remains central to its clinical franchise.Subsequent deals extended the platform into higher-growth niches. The 2019 acquisition of BioTek Instruments for 1.17 billion dollars added cell analysis instrumentation, and the 2024 purchase of BIOVECTRA for 925 million dollars moved Agilent into biologics contract development and manufacturing, a services adjacency tied to the growth of biologic drugs.The acquisition philosophy is to add capabilities in fast-growing, recurring-revenue areas rather than to chase scale. Agilent has integrated these platforms into its services and consumables model, and the pattern reflects a deliberate tilt away from cyclical instruments toward the durable franchises that underpin its margins.
Acquisition Timeline
Merger & Spin-off History
Merger & Spin-off Analysis
Agilent structural history is defined by two separations. It was itself created by a spin-off, when Hewlett-Packard carved out its test and measurement and chemical analysis businesses as Agilent in 1999, completing the separation in 2000 in what was then a very large technology divestiture.The second defining event was Agilent own 2014 spin-off of its electronic measurement business as Keysight Technologies. That transaction split the company in two, leaving Agilent focused on life sciences, diagnostics and applied chemical markets while Keysight took the electronics measurement heritage.Since the Keysight separation, Agilent structural evolution has come through acquisitions rather than further large spin-offs. The pattern of carving the company down to a focused life sciences and diagnostics platform, then building that platform through targeted deals, reflects a consistent strategy of concentrating on higher-growth, recurring-revenue markets.
Ownership History
Ownership History Analysis
Agilent Technologies carries the measurement heritage of Hewlett-Packard, one of the foundational companies of Silicon Valley. When Hewlett-Packard split in 1999, it spun off its test and measurement, chemical analysis and semiconductor-related businesses as Agilent, which completed the largest initial public offering in Silicon Valley history to that point.Over the following years Agilent narrowed its focus, divesting semiconductor and electronics operations and, in 2014, spinning off its electronic measurement arm as Keysight. That left a company concentrated on life sciences, diagnostics and applied chemical analysis, which it has grown organically and through acquisitions such as Dako and BioTek.Today Agilent is a focused life sciences tools and diagnostics company led by chief executive Padraig McDonnell, with fiscal 2025 revenue of 6.95 billion dollars. Its history is one of methodical portfolio sharpening, transforming a broad Hewlett-Packard offshoot into a focused instruments, services and diagnostics leader.
Ownership Explained
Agilent Technologies is a widely held public company listed on the New York Stock Exchange with no controlling shareholder. Its largest owners are index managers, led by Vanguard, BlackRock and State Street. Padraig McDonnell serves as chief executive officer, with Koh Boon Hwee as chairman. Created as a 1999 spin-off from Hewlett-Packard, Agilent has been an independent public company throughout its life.
With dispersed ownership and one-share one-vote governance, Agilent answers fully to public shareholders and the capital markets. That accountability has driven a multi-year sharpening of the portfolio, including the spin-off of the electronics business and an operating overhaul known as the Ignite transformation. Management returns capital through dividends and buybacks while investing in life sciences and diagnostics. The absence of a controlling owner keeps strategy subject to market discipline.